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           The transfer of defi  ned TCR genes into human 
T cells appears to be a promising new strategy 
for redirecting T cells against cancer cells. In 
this approach, TCR genes with specifi  city for a 
known tumor antigen are introduced into the 
T cells of a patient whose tumor expresses the 
antigen and shares the MHC-restricting allele, 
and the modifi  ed cells are then expanded in 
vitro and infused back into the patient (  1  ). A 
recent clinical study demonstrated the feasibility 
of this strategy (  2  ), but the observed clinical ef-
fi  cacy was limited, in part because of the low 
avidity of the transduced T cells. Thus, a major 
challenge is to defi  ne means to improve the 
avidity of T cells transduced with a potentially 
tumor-reactive TCR, particularly in the con-
text of the generally low affi   nity of available 
tumor-reactive TCRs. Besides selecting tu-
mor-reactive TCRs with the highest identifi  -
able affi   nity (  3  –  5  ), strategies to increase TCR 
affi   nity before transduction (  6, 7  ) or the (func-
tional) avidity of the resulting TCR-transduced 
T cells (  8, 9  ) should be explored. In this context, 
  “  affi   nity  ”   will be defi   ned as the strength of 
binding of one receptor with its ligand,   “  avid-
ity  ”   as the strength of binding between multiple 
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  Adoptive transfer of T lymphocytes transduced with a T cell receptor (TCR) to impart tumor 
reactivity has been reported as a potential strategy to redirect immune responses to target 
cancer cells (Schumacher, T.N. 2002.   Nat. Rev. Immunol.   2:512  –  519). However, the affi  nity 
of most TCRs specifi  c for shared tumor antigens that can be isolated is usually low. Thus, 
strategies to increase the affi  nity of TCRs or the functional avidity of TCR-transduced 
T cells might be therapeutically benefi  cial. Because glycosylation affects the fl  exibility, 
movement, and interactions of surface molecules, we tested if selectively removing con-
served   N  -glycoslyation sites in the constant regions of TCR      or      chains could increase 
the functional avidity of T cells transduced with such modifi  ed TCRs. We observed enhanced 
functional avidity and improved recognition of tumor cells by T cells harboring TCR chains 
with reduced   N  -glycosylation (    TCR) as compared with T cells with wild-type (WT) TCR 
chains. T cells transduced with WT or     TCR chains bound tetramer equivalently at 4  °  C, but 
tetramer binding was enhanced at 37  °  C, predominantly as a result of reduced tetramer 
dissociation. This suggested a temperature-dependent mechanism such as TCR movement in 
the cell surface or structural changes of the TCR allowing improved multimerization. This 
strategy was effective with mouse and human TCRs specifi  c for different antigens and, 
thus, should be readily translated to TCRs with any specifi  city. 
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demonstrate with several TCRs recognizing diff  erent anti-
gens that the removal by point mutation of defi  ned   N  -glyco-
sylation motifs in the constant domains of TCR chains can 
increase the functional avidity of T cells transduced with these 
TCRs, and that this translates into enhanced recognition of 
tumor cells. As these   N  -glycosylation sites in the constant do-
main are conserved in all TCRs, this strategy should be easily 
translated to TCRs with any specifi  city. 
    RESULTS   
  Selective   N  -deglycosylation of TCR chains increases 
functional avidity of TCR-transduced 58                       cells as 
compared with 58                       cells transduced with WT TCR chains 
  To determine if reducing   N  -glycosylation of TCR chains can 
aff  ect functional T cell avidity, we fi  rst analyzed the      and      
chain sequence of two mouse (  3, 4  ) and one human (  9  ) TCRs 
for characteristic   N  -glycosylation sites (  N-X-S/T;   see Materi-
als and methods;   Fig. 1  ), as located according to the ImMuno-
GeneTics (IMGT) nomenclature (  20  ).     N  -glycosylation sites 
were detected in the variable domain of all analyzed      chains 
but not in the variable domain of any of the tested      chains 
(  Fig. 1  ). The mouse constant      chain harbors two   N  -glycosyl-
ation sites (c-90 and c-113). Although the location of these 
  N  -glycosylation sites are conserved in the human constant      
chain (c-90 and c-109), the threonine of the motifs is replaced 
by an equally acceptable serine residue. The human constant 
     chain also has an additional   N  -glycosylation site at position 
c-36. The mouse constant      chain has three   N  -glycosylation 
sites, whereas the human constant      chain harbors only a single 
receptors and their ligands, and   “  functional avidity  ”   as the 
sensitivity of a T cell response to a target cell expressing the 
relevant peptide  –  MHCs (pMHCs). 
  Diff  erent strategies have been examined to increase the 
affi   nity of TCRs used for transduction. TCR phage (  7  ) and 
yeast (  6  ) displays have been used as formats to express TCR 
chains and to then generate mutants that can be screened ex 
vivo for increased affi   nity. With these approaches, a library 
of TCR chains can be created generally after random muta-
tion of defi  ned regions, such as CDR3, known to be impor-
tant in recognition; the library expressed on the surface of 
the phage or yeast; the expressed mutated TCR chains 
screened by tetramer binding for increased affi   nity; and the 
cDNA encoding the highest affi   nity chains extracted, char-
acterized, and subsequently used for transduction. Conse-
quently, these display strategies can be very eff  ective but are 
cumbersome and must be individualized for each TCR. 
Furthermore, not every TCR can be successfully expressed 
and modifi  ed by these technically challenging display strate-
gies in nonmammalian systems (unpublished data), empha-
sizing the need for alternative techniques to increase TCR 
affi   nity or functional avidity of a T cell. 
  The functional avidity of a T cell, as refl  ected by respon-
siveness to antigen, is modulated by T cell surface   O  - or   N  -
glycosylation (  10, 11  ), with increased glycosylation of T cell 
surface proteins associated with an increased activation thresh-
old. This has been reported to contribute to the higher acti-
vation thresholds of tolerant T cells (  12  ), aged as compared 
with young T cells (  13, 14  ), and naive as compared with acti-
vated or memory T cells (  15, 16  ), and molecules such as 
CD43 and CD45 have been reported to be directly involved. 
The reciprocal event, decreased glycosylation of surface pro-
teins, has been reported to result in a decreased activation 
threshold. For example, decreased glycosylation of CD8 dur-
ing thymic development is associated with increased affi   nity 
of CD8 with pMHC and, subsequently, improved signaling 
(  17, 18  ). Moreover, a general defi  ciency in     1,6   N  -acetylglu-
cosaminyltransferase V (Mgat5) in mice, an enzyme in the 
  N  -glycosylation pathway, mediates increased T cell activity 
in vitro and results in autoimmune disease in vivo (  19  ). Al-
though defi  ciency of this   N  -glycosylation pathway enzyme in 
mice resulted in reduced   N  -glycosylation of all proteins, the 
reduced   N  -glycosylation of the TCRs appeared to specifi  -
cally result in increased TCR mobility at the cell surface, 
enhanced recruitment to the synapse (TCR clustering), 
improved TCR engagement/down-modulation, and, conse-
quently, enhanced functional avidity of the T cells. To test if 
selectively reducing   N  -glycosylation of TCR chains might 
achieve some of these eff  ects,   N  -glycosylation of cloned TCR 
genes was prevented by sequentially deleting before expres-
sion   N  -glycosylation motifs (asparagine  –  any amino acid  –
  serine/threonine[N-X-S/T]) in the      and/or      chain by 
changing N to glutamine (Q) by site-directed mutagenesis. 
The WT and/or modifi  ed TCR chains were expressed in 
hybridomas or human T cells, and TCR expression, tetramer 
staining, and functional avidity of the T cells was assessed. We 
    Figure 1.           N  -glycosylation sites in mouse and human TCR chains.  
(A) List of the cloned TCR chains investigated.   N  -glycosylation sites in 
these (B) TCR      and (C) TCR      chains. Sites harboring the   N -glycosyl-
ation motif (  N-X-S/T  ) are in bold and are underlined (according to the 
IMGT nomenclature; reference   20  ).     JEM VOL. 206, February 16, 2009 
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and Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20082487/DC1). Thus, 58                       cells transduced 
with combinations of     TCR chains exhibited similar levels 
of TCR expression as compared with 58                       cells trans-
duced with WT TCR chains and exhibited no initial diff  er-
ence in specifi  c tetramer binding. 
  To assess functional avidity of transduced 58                       cells, 
IL-2 secretion was assessed in response to K562-A2 cells pulsed 
with titrated amounts of p53  264-272   peptide. The peptide con-
centration required to reach half-maximal IL-2 secretion 
(EC50) was calculated and transformed to log scale (log  EC50  ). 
58                       cells expressing v    3  WT  /v    3  WT   TCR had a log  EC50   of 
  –  6   ±   0.1 M, and 58                       cells expressing v    3  c-90  /v    3  WT   had 
  N  -glycosylation site at position c-85.6, which corresponds to 
the mouse   N  -glycosylation site at position c-84.5. 
  The potential contribution of distinct glycosylation sites 
within TCR chains to modulating activation after antigen 
encounter was assessed by modifying WT mouse v    3  WT   and 
v    3  WT  TCR chains isolated from a mouse CD8  +   T cell clone 
that had been derived from a transgenic mouse expressing 
human HLA-A*0201 (HLA-A2) and was specifi  c  for  the 
HLA-A2  –  restricted p53-derived epitope p53  264-272   (  4  ). Fur-
thermore, this TCR is CD8 independent, thus allowing anal-
ysis of the role of CD8 in the function of a deglycosylated 
TCR chain.   N  -glycosylation of TCR chains was prevented 
at specifi  c sites (TCR chains with reduced   N  -glycosylation 
[    TCR]) by mutating N of the   N  -glycosylation motif   N-X-
S/T   to Q at position 84C (v    3  v-84C  ) in the variable domain 
of v    3 or at position 90 (v    3  c-90  ) or 113 (v    3  c-113  ) in the con-
stant domain of the      chain, or at position 1.3 (v    3  c-1.3  ), 84.5 
(v    3  c-84.5  ), or 116 (v    3  c-116  ) in the constant domain of the 
v    3 chain (v    3  116  ; residues noted according to IMGT [  20  ]; 
  Fig. 1  ). 58                       thymoma cells were retrovirally transduced 
with either the WT      and      chain or a combination of a WT 
chain and the corresponding          or          TCR chain, selected 
with antibiotics, stained with an antibody to the mouse      
TCR chain, and analyzed by fl  ow cytometry. Only 58                       
cells transduced with both v    3 and v    3 chains expressed the 
v    3 chain at the cell surface (unpublished data), consistent 
with the requirement for the assembly of paired heterodimeric 
TCR chains to achieve surface expression. Despite multiple 
attempts, we were unable to generate 58                       cells express-
ing the v    3  c-1.3   chain, perhaps because of improper folding of 
this modifi  ed chain, and this modifi  cation was therefore not 
further pursued. After transduction of 58                       cells with WT 
v    3  WT  /v    3  WT   chains or all other combinations of      and WT 
TCR chains,     80% of cells expressed the v    3 TCR, with a 
mean fl  uorescence intensity (MFI) of     250 for v    3 expres-
sion (  Fig. 2 A  ; and Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20082487/DC1).   Because the      chain 
is required for surface expression of the      chain, these results 
also suggest that the mutations do not aff  ect expression, with 
equivalent amounts of      and WT v    3 chains expressed at the 
cell surface with v    3 chains. Thus, 58                       cells transduced 
with combinations of      and WT chains exhibited similar ef-
fi  ciencies of expression for pairs of all of the introduced          
TCR chains, with the exception of the v    3  c-1.3   chain. 
  To assess tetramer binding of the diff  erent TCR chains, 
58                       cells mock transduced or transduced with WT only 
or combinations of WT and     TCR chains were incubated 
with the p53  264-272   tetramer at 4  °  C for analysis by fl  ow cy-
tometry of TCR  –  pMHC interactions in the absence of tem-
perature-dependent mechanisms such as increased membrane 
fl  uidity, diff  usion rates, and conformational changes. Mock-
transduced 58                       cells did not bind the p53  264-272   tetramer. 
In contrast,     70% of the 58                       cells transduced with any 
of the pairs of TCR chains bound the p53  264-272   tetramer, and 
the MFI of the tetramer-positive populations was     40  –  70 
for 58                       cells expressing WT and     TCR chains (  Fig. 2 B  ; 
    Figure 2.         Analysis of the v    3v    3 TCR  –  transduced hybridoma cell 
line 58                      .   Mock (thin line), v   3 WT /v  3 WT   (bold line), and v   3 c-90 /v  3 WT  
(dashed line) TCR  –  transduced 58                 cells were stained with (A) anti-
mu   TCR – PE  or  (B)  p53 264-272  Tet  –  PE at 4  °  C and were analyzed by fl  ow cy-
tometry. (C) v   3 WT /v  3 WT   (   ) and v   3 c-90 /v  3 WT   (  )  TCR – transduced 
58                 cells were co-cultured with K562-A2 targets pulsed with titrated 
amounts of p53  264-272   peptide, and IL-2 secretion was measured by ELISA. 
Data are representative of at least two independent experiments. (D)    lo-
g  EC50   of     TCR-transduced T cells as compared with WT TCR  –  transduced 
T cells was determined as log  EC50          log EC50WT  . Statistical signifi  cance was 
assessed by a   t   test (*, P   <   0.05; error bars are SEM) if two or more indepen-
dent cytokine titration assays were available for the calculation of    log EC50 .   466 INCREASING FUNCTIONAL AVIDITY OF TCR-REDIRECTED T CELLS   | Kuball et al. 
lent (both 97% tetramer positive; v    3  WT  /v    3  WT  , MFI of 66; 
v    3  c-90  /v    3  WT  , MFI of 57;   Fig. 3 B  ). Functional avidity of 
the CD4  +   T cells transduced with v    3  WT  /v    3  WT   and v    3  c-
90  /v    3  WT   TCR chains was then determined by incubating 
the T cells with T2 cells pulsed with titrated amounts of 
p53  264-272   peptide. Supernatant was harvested 48 h later, 
IFN-     secretion was determined by ELISA, and the peptide 
a log  EC50   of   –  6.9   ±   0.3 M (  Fig. 2 C  ), revealing a 0.9-log in-
creased avidity for the v    3  c-90  /v    3  WT    –   compared with WT 
TCR  –  transduced cells (    log  EC50   v    3  c-90   = 0.9;   Fig. 2 D  ). IL-2 
secretion in response to peptide-loaded K562-A2 cells was also 
measured for 58                       cells transduced with the other mutants 
(not depicted), and the     log  EC50   was calculated (v    3  v-84C  , 0.4; 
v    3  c-113  , 0.2; v    3  v-84C,c-90,c-113  , 0.5; v    3  c-84.5  , 0.3; v    3  c-116  , 0.5; 
v    3  c-84.5,c-116  , 0.5; and v    3  v-84C,c-90,c-113  /v    3  c-84.5,c-116  , 0.5;   
Fig. 2 D  ).   t   tests were performed if two or more independent 
cytokine titration assays were available for the calculation of 
    log  EC50   to determine the signifi  cance of the observed im-
provement in functional avidity (v    3  c-90  , P = 0.01; v    3  c-84.5  , 
P = 0.44; v    3  c-116  , P = 0.06; v    3  c-84.5,c-116  , P = 0.07; v    3  v-
84C,c-90,c-113  /v    3  c-84.5,c-116  , P = 0.02;   Fig. 2 D  ). In summary, de-
spite equivalent TCR expression and equivalent binding at 
4  °  C of specifi  c tetramer by 58                       cells transduced with WT 
and    TCR, reduced  N  -glycosylation of TCR chains increased 
IL-2 secretion of 58                       cells after antigen encounter, and 
was statistically signifi  cant (P   <   0.05) for 58                       cells trans-
duced with v    3  c-90   and v    3  v-84C,c-90,c-113  /v    3  c-84.5,c-116   chains. 
  Enhanced functional avidity of human T cells transduced 
with the partially deglycosylated TCR chain v    3  c-90   
in the absence of the CD8 coreceptor 
  To determine if the eff  ect of partial TCR chain deglycosyl-
ation in human T cells refl  ected altered interactions with the 
CD8 coreceptor, human CD4  +   and CD8  +   T cells were retro-
virally transduced with the HLA-A2  –  restricted p53  264-272    –  spe-
cifi  c mouse WT or     TCR, as indicated in Materials and 
methods. We focused our analysis on the v    3  c-90  /v    3  WT   
    TCR chain pair that had the most prominent change in 
avidity in 58                       cells. CD4  +   T cells expressing mouse 
v    3  WT  /v    3  WT   or v    3  c-90  /v    3  WT   TCR chains were sorted for 
equivalent amounts of v    3 surface expression and were ex-
panded (both were 99% v    3 positive; v    3  WT  /v    3  WT  , MFI of 
1,050; v    3  c-90  /v    3  WT  , MFI of 1,100;   Fig. 3 A  ).   Expression of 
the v    3 chain could not be monitored directly because of the 
lack of a commercially available antibody. However, mouse 
TCR chains are preferentially expressed with each other and 
not with human endogenous TCR chains (  8, 21, 22  ), and 
measuring the introduced      chain should be a good general 
indication of expression of the introduced mouse      chain in 
these polyclonal populations. Moreover, v    3 expression was 
indirectly assessed by isolating mRNA from the transduced 
T cells, reverse transcribing the mRNA into cDNA, analyz-
ing the product with PCR primers detecting the unique 
CDR3 domain of the TCR      chain, and normalizing to the 
number of     -actin copies. Equivalent amounts (1:1 ratio) of 
v    3  WT   and v    3  c-90   RNA levels were detected in cells previ-
ously selected based on equivalent v    3 surface expression. 
  To assess tetramer binding of WT and     TCR chain 
heterodimers in human T cells in the absence of the CD8 
coreceptor, transduced CD4  +   T cells were incubated with 
p53  264-272   tetramer at 4  °  C and analyzed by fl  ow cytometry. 
Tetramer binding of CD4  +   T cells transduced with v    3  WT  /
v    3  WT   and v    3  c-90  /v    3  WT   TCR chains was almost equiva-
    Figure 3.         Analysis of v    3v    3 TCR  –  transduced CD4  +   T cells.   Mock 
(thin line), v   3 WT /v  3 WT   (bold line), and v   3 c-90 /v  3 WT   (dashed  line) 
TCR – transduced  CD4 +   T cells were stained with (A) anti-mu   TCR – Pcy5 
or (B) p53  264-272  Tet  –  PE at 4  °  C and were analyzed by fl  ow cytometry. 
(C) v   3 WT /v  3 WT   (   ) and v   3 c-90 /v  3 WT   (  )  TCR – transduced  CD4 +  
T cells were co-cultured with T2 cells pulsed with titrated amounts of 
p53  264-272   peptide.  IFN-    secretion was measured by ELISA after 48 h. 
(D) Intracellular IFN-     secretion of v   3 WT /v  3 WT   and  v  3 c-90 /v  3 WT  
TCR – transduced  CD4 +   T cells was determined after a 5-h coincubation 
with T2 cells pulsed with 10     5   M  WT1 126-134   or  p53 264-272   peptide.  Data 
are representative of at least two independent experiments.     JEM VOL. 206, February 16, 2009 
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though the presence of the coreceptor CD8 increased the 
functional avidity of this class I  –  restricted T cell response, re-
cruitment of T cells and production of cytokine per cell was 
still further increased in the presence of     TCR as compared 
with WT TCR chains. 
  To assess the impact of a     TCR in transduced T cells on 
recognition of cells expressing more physiological levels of an-
tigen, mock-transduced T cells and v    3  c-90  /v    3  WT   or v    3  WT  /
v    3  WT   TCR  –  transduced CD8  +   T cells were tested for recog-
nition of the HLA-A2  –  positive p53-negative cell line Soas2, 
and the HLA-A2  –  positive p53-overexpressing tumor cell lines 
MDAMB231, SW480, and MZ1851RC in a 5-h   51  Cr-release 
assay at a low eff  ector/target ratio of 0.3:1 (  Fig. 4 B  ). No 
T cell lines lysed the negative control Saos2, and mock-trans-
duced T cells did not lyse any tumor targets. In contrast, the 
concentration inducing half-maximal IFN-     secretion was 
determined and transformed to log  EC50  . The v    3  WT  /v    3  WT    –
  transduced T cells had a log  EC50   for IFN-     secretion of     7.5 
  ±  0.1 M (  Fig. 3 C  ), whereas the V    3  c-90  /v    3  WT   TCR  –  trans-
duced CD4  +   T cells had a log  EC50   of     7.9   ±   0.1 M (  Fig. 3 C  ). 
Again,     log  EC50   (0.4) was calculated from two independent 
assays (P = 0.02). Furthermore, as compared with WT 
TCR  –  transduced CD4  +   T cells, the maximal IFN-     cyto-
kine secretion was approximately threefold higher for CD4  +   
T cells transduced with v    3  c-90  /v    3  WT   TCR chains (v    3  WT  /
v    3  WT  , 3,258   ±   1,638 pg/ml; v    3  c-90  /v    3  WT  , 9,487   ±   382 
pg/ml). Thus, despite equivalent amounts of TCR surface 
expression and tetramer binding by the transduced CD4  +   
T cells, CD4  +   T cells transduced with v    3  c-90  /v    3  WT   TCR 
chains had a greater ability to respond to antigen and produce 
IFN-     than CD4  +   T cells expressing v    3  WT  /v    3  WT   chains. 
  To determine if the observed higher maximal IFN-     cy-
tokine secretion by v    3  c-90  /v    3  WT   compared with v    3  WT  /
v    3  WT   TCR  –  transduced T cells refl  ected recruitment of a 
larger fraction of antigen-specifi   c cells, or more cytokine 
production from each activated cell, transduced T cells were 
incubated for 5 h with p53  264-272   or WT1  126-134   control pep-
tide-pulsed (10      5   M) target cells, secretion was blocked with 
Brefeldin A, and intracellular IFN-     production was deter-
mined by fl  ow cytometry. 11.5% of CD4  +   T cells transduced 
with v    3  WT  /v    3  WT   and 34.1% of CD4  +   T cells transduced 
with v    3  c-90  /v    3  WT   stained positive for IFN-     (  Fig. 3 D  ). 
Furthermore, the MFI of IFN-      –  positive cells, an indicator 
for the mean cytokine production per cell, was 20 for v    3  WT  /
v    3  WT    –   and 43 for v    3  c-90  /v    3  WT    –  transduced T cells, sug-
gesting that the diff  erence refl  ected both recruitment of more 
cells and production of more cytokine per cell in cells ex-
pressing the v    3  c-90  /v    3  WT   TCR. 
  Gain of functional avidity mediated by the v    3  c-90   
TCR chain persists in the presence of the CD8 coreceptor 
  To determine if the presence of the CD8  +   coreceptor modi-
fi   es the observed improvement in functional avidity with 
    TCR chains, CD8  +   T cells transduced with either v    3  WT  /
v    3  WT   or v    3  c-90  /v    3  WT   were selected for equivalent v    3 
TCR surface expression. To determine      chain expression 
in cells sorted for equivalent v    3 TCR surface expression, 
mRNA was again isolated from transduced T cells, reverse 
transcribed into cDNA, amplifi  ed by PCR with primers spe-
cifi  c for the TCR      chain and     -actin, and normalized to     -
actin copies. Equivalent amounts (1:1 ratio) of v    3  WT   and 
v    3  c-90   RNA were detected. Transduced CD8  +   T cells se-
lected for equivalent v    3 TCR surface expression by fl  ow 
cytometry and controlled for equivalent v    3 TCR expres-
sion by RT-PCR were incubated for 5 h with p53  264-272   or 
WT1  126-134   control peptide-pulsed (10      5   M) T2 cells, secre-
tion was blocked with Brefeldin A, and intracellular IFN-     
production was determined by fl   ow cytometry. 42.5% of 
v    3  c-90  /v    3  WT    –  transduced CD8  +   T cells produced IFN-     
(MFI of 40), whereas only 27.7% of cells expressing v    3  WT  /
v    3  WT   produced IFN-     (MFI of 29;   Fig. 4 A  ).   Thus, al-
    Figure 4.         Analysis of v    3v    3 TCR  –  transduced CD8  +   T cells.  
(A) Intracellular IFN-     secretion of v   3 WT /v  3 WT   and  v  3 c-90 /v  3 WT   TCR –
 transduced  CD8 +   T cells was determined after a 5-h coincubation with 
T2 cells pulsed with 10     5   M  WT1 126-134   or  p53 264-272   peptide. (B) Mock (gray 
bar), v   3 WT /v  3 WT   (white bar), and v   3 c-90 /v  3 WT   (black  bar)  TCR – trans-
duced CD8  +   T cells were tested for recognition of the HLA-A2  + p53       cell 
line Saos2 and the p53-overexpressing cell lines MDAMB231 (MDAMB), 
SW480, and MZ1851RC (MZ1851) in a 5-h   51  Cr-release assay (  t   test: *, P   <   
0.05; **, P   <   0.01; error bars are SEM). All assays were performed in dupli-
cates. All data are representative of at least two independent experiments.     468 INCREASING FUNCTIONAL AVIDITY OF TCR-REDIRECTED T CELLS   | Kuball et al. 
v    3  WT   TCR, 100 nM; and CD4  +  v    3  WT  /v    3  WT  ,   ≥  414 nM), 
consistent with the higher functional avidity previously 
observed for     TCR as compared with WT TCR  –  trans-
duced T cells. 
  TCR internalization of WT and     TCR in transduced T cells 
after antigen-specifi  c stimulation 
  Globally reduced   N  -glycosylation in T cells has been sug-
gested to improve T cell signaling by improving mobility of 
the TCR on the cell membrane, thereby enhancing TCR 
recruitment to the synapse and increasing the frequency of 
TCR  –  pMHC interaction, which results in augmented sig-
naling and greater TCR internalization/endocytosis (  19  ). 
We examined whether depletion of a single   N  -glycosylation 
v    3  c-90  /v    3  WT   and v    3  WT  /v    3  WT   TCR  –  transduced CD8  +   
T cells lysed all of the p53-overexpressing cell lines. Greater 
lysis of tumor targets was achieved with T cells transduced 
with the     TCR chains, which was signifi  cantly diff  erent by a 
  t   test from lysis by T cells transduced with WT TCR chains 
(    TCR/WT TCR: MZ1851RC, 23%/11%, P   <   0.01; MD-
AMB231, 26%/14%, P   <   0.01; SW480, 55%/30%, P   <   0.05). 
Thus, substituting v    3  WT   with v    3  c-90   improved lysis of cells 
that endogenously process and present antigen. 
  Tetramer binding of T cells transduced with WT 
and partially deglycosylated TCR chains 
  Functional avidity of TCR-transduced T cells has been re-
ported to correlate with tetramer binding (  9  ). However, our 
results with transduced 58                      , CD4  +  , and CD8  +   T cells 
indicated an increase in functional avidity for v    3  c-90  /v    3  WT    –   
compared with v    3  WT  /v    3  WT    –  transduced cells despite ap-
parently equivalent tetramer binding (  Figs. 2  –  4  ). Because 
these tetramer-binding experiments were performed at 4  °  C, 
which precludes temperature-dependent events such as 
increased membrane fl  uidity and conformational changes, 
tetramer binding was reanalyzed at 37  °  C to permit temp-
erature-dependent changes that might infl   uence TCR  –
  pMHC binding (  23  –  25  ), and the K  D   of the TCR-pMHC 
interaction was calculated by Scatchard analysis, as indicated 
in Materials and methods. The v    3  WT  /v    3  WT   and v    3  c-90  /
v    3  WT   TCR  –  transduced CD4  +   T cells had a K  D   of 73 and 46 
nM, respectively, and the v    3  WT  /v    3  WT   and v    3  c-90  /v    3  WT   
TCR  –  transduced CD8  +   T cells had a K  D   of 19 and 15 nM, 
respectively (  Table I   and   Fig. 5, A and B  ).   Thus, in contrast 
to tetramer binding at 4  °  C, analysis at 37  °  C revealed that the 
v    3  c-90  /v    3  WT   TCR  –  transduced CD4  +   T cells bound tetra-
mer with a lower K  D   than WT receptors, whereas CD8  +   T 
cells transduced with the v    3  c-90  /v    3  WT   TCR appeared to 
achieve only a slightly improved K  D   compared with WT 
TCR  –  transduced T cells. To more precisely analyze the K  D   
changes in CD4  +   and CD8  +   T cells, the K  D   was reanalyzed 
by determining tetramer association and dissociation rather 
than the previous Scatchard analysis, which permitted deter-
mining the association (k  on  ) and dissociation (k  off    ) rates. As 
described in Materials and methods, k  ob   was assessed during 
tetramer association; t  1/2   and k  off     were assessed during tetra-
mer dissociation; and k  on   and K  D   were then derived (  Table I   
and   Fig. 5, C  –  F  ). k  off    , the dissociation constant of the pMHC 
from the TCR, was approximately ninefold longer for CD8  +   
and approximately fourfold longer for CD4  +      TCR as com-
pared with WT TCRs (CD8  +  v    3  c-90  /v    3  WT  , 0.26 min      1  ; 
CD8  +  v    3  WT  /v    3  WT  , 0.03 min      1  ; CD4  +  v    3  c-90  /v    3  WT   
TCR, 0.29 min      1  ; and CD4  +  v    3  WT  /v    3  WT  , 0.07 min      1  ). 
k  on  , the association constant of the TCR to the pMHC com-
plex for both WT and     TCR  –  transduced CD8  +   T cells, 
was 0.01 nM      1  min      1  , 0.0007 nM      1  min      1  , and   ≤  0.0007 
nM      1  min      1   for      and WT TCR CD4  +   T cells. These more 
precise rates now resulted in a lower calculated K  D   for 
    TCR-transduced CD8  +   and CD4  +   T cells (CD8  +  v    3  c-90  /
v    3  WT   TCR, 3 nM; CD8  +  v    3  WT  /v    3  WT  , 26 nM; CD4  +  v    3  c-90  /
    Figure 5.         Tetramer binding of WT and     TCR  –  transduced T cells.  
(A) v   3 WT /v  3 WT   (bold line) and v   3 c-90 /v  3 WT   (dashed  line)  TCR – trans-
duced CD4  +   T cells were stained with p53  264-272 Tet – PE  at  37 ° C  at  the  indi-
cated tetramer concentrations. (B) v   3 WT /v  3 WT   (   ) and v   3 c-90 /v  3 WT   (  ) 
TCR – transduced  CD4 +   T cells were tested for binding to p53  264-272 Tet – PE 
after 60 min by fl  ow cytometry as indicated in A, and the avidity (K  D )  of 
tetramer binding to T cells was determined by Scatchard analysis, with the 
95% confi  dence band indicated by thin dashed lines. p53  264-272 Tet – PE  bind-
ing to v   3 WT /v  3 WT   (   ) and v   3 c-90 /v  3 WT   (  )  TCR – transduced  (C)  CD8 +  
and (D) CD4  +   T cells was determined at 37  °  C at the indicated time points 
by fl  ow cytometry, and t  1/2   for half maximal binding was determined. After 
p53  264-272 Tet – PE  binding  to  v  3 WT /v  3 WT   (  )  and  v  3 c-90 /v  3 WT   (  )  TCR –
  transduced (E) CD8  +   and (F) CD4  +   T cells, the cells were washed and incu-
bated with the HLA class I blocking antibody W6/32 at 37  °  C. The percent 
inhibition of tetramer binding and t  1/2   for inhibition were calculated. All 
data are representative of at least two independent experiments.     JEM VOL. 206, February 16, 2009 
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jem.20082487/DC1). Thus,      and WT TCR chains were 
equivalently internalized after antigen encounter. 
  Depleting   N  -glycosylation motifs in the constant domain 
improves functional avidity of TCR with other specifi  cities 
in transduced T cells 
  The enhanced avidity of v    3  c-90  /v    3  WT   as compared with 
v    3  WT  /v    3  WT    –  transduced T cells could potentially be a 
unique feature of the p53  264-272    –  specifi  c v    3/v    3 TCR 
chains. To determine if elimination of   N  -glycosylation mod-
ifi  cations could be of more general use to increase the avidity 
of T cells transduced with other TCRs, a mouse HLA-A2  –
  restricted TCR with reactivity against the human tumor an-
tigen MDM2  81-88   (v    13-D3  WT  /v    6  WT  ) was modifi  ed at the 
unique position v-24 in the variable domain (v    13-D3  v-24  ) 
or at the positions previously found to be most eff  ective in 
improving the functional avidity of T cells for the v    3/v    3 
TCR chains: c-90 in the constant domain of the      chain 
motif from a TCR chain can also facilitate this process, and 
used TCR internalization as the measurable objective end-
point. Therefore, v    3  c-90  /v    3  WT   or v    3  WT  /v    3  WT   TCR  –
  transduced CD4  +   T cells were co-cultured with T2 cells 
pulsed with 10      6   or 10      8   M of p53  264-272   peptide, and surface 
expression of the introduced TCR      chain was assessed be-
fore and at 2, 4, and 6 h after stimulation by fl  ow cytometry. 
For the comparisons, surface expression of the introduced 
mouse TCR      chain before antigen encounter was set as 
100%, no detectable surface expression of mouse TCR      
chain was set as 0%, and the surface expression after antigen 
encounter was calculated as the percentage of total TCR      
chain surface expression before antigen encounter. A maxi-
mal 80% down-regulation of the introduced mouse TCR 
     chain was observed at 10      6   M, and 50% TCR      chain 
down-regulation was observed at 10      8   M for both v    3  c-90  /
v    3  WT   and v    3  WT  /v    3  WT   TCR  –  transduced CD4  +   T cells 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
    Table I.        Tetramer-binding avidity (K  D  ) of TCR-transduced human T lymphocytes 
K  D   (K  D   =     1/slope 
determined  
  by Scatchard plot)
K  D   (determined  
  by Tet association  
  and Tet 
dissociation)
Tet association Tet dissociation  
  (inhibition with W6/32)
k  on    
  calculation
K  D   = k  off  /k  on t  1/2 k  ob t  1/2 k  off  k  on   = (k  ob        k  off  )/  
  ligand concentration
  nM   nM   min    min     1      min    min     1     nM     1 min    1   
CD4  +    
  v    3  WT 
73 (slope:  
      0.014   ±   0.003)
  ≥  414 5.2  
  (95% CI 
interval:  
  2.4 to     )
0.13   ±   0.06 2.4  
  (95% CI 
interval:  
  1.1 to     )
0.29   ±   0.13   ≤  0.0007
CD4  +    
  v    3  c-90 
46 (slope:  
      0.032   ±   0.011)
100   ±   33 5.5  
  (95% CI 
interval:  
  3.2  –  18.9)
0.13   ±   0.04 10  
  (95% CI 
interval:  
  7.1  –  17.1)
0.07   ±   0.01 0.0007   ±   0.0001
CD8  +    
  v    3  WT 
19 (slope:  
      0.052   ±   0.003)
26   ±   7 8.1  
  (95% CI 
interval:  
  6.6  –  11.1)
0.85   ±   0.01 2.7  
  (95% CI 
interval:  
  1.6  –  9.3)
0.26   ±   0.07 0.01   ±   0.01
CD8  +   
v    3  c-90 
15 (slope:  
      0.065   ±   0.008)
3   ±   1 7  
  (95% CI 
interval:  
  4.4  –  17.9)
0.99   ±   0.02 21.3  
  (95% CI 
interval:  
  12.5  –  72)
0.03   ±   0.01 0.01   ±   0.01
CD8  +    
  v    13-D3  WT 
14 (slope:  
      0.074   ±   0.026)
30   ±   3 8.3  
  (95% CI 
interval:  
  6.6  –  11.1)
0.08   ±   0.01 26.5  
  (95% CI 
interval:  
  7.8 to     )
0.03   ±   0.01 0.001   ±   0.001
CD8  +    
  v    13-D3  c-90 
12 (slope:  
      0.083   ±   0.043)
10   ±   1 7.1  
  (95% CI 
interval:  
  4.4  –  17.9)
0.1   ±   0.02 64  
  (95% CI 
interval:  
  10.8 to     )
0.01   ±   0.01 0.001   ±   0.001
CD8  +    
  v    21  WT 
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
CD8  +    
  v    21  c-36 
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
n.d., not determined because of the loss of tetramer binding at 37  °  C as compared with 0  °  C.470 INCREASING FUNCTIONAL AVIDITY OF TCR-REDIRECTED T CELLS   | Kuball et al. 
ity, with 20.6% of cells producing cytokine as compared with 
6.1% for WT TCR  –  transduced T cells (  Fig. 6 B  ). After trans-
duction with v    21  v-83  /v    21  WT  , v    21  c-90  /v    21  WT  , v    21  c-109  /
v    21  WT  , or v    21  WT  /v    21  c-85.6  , 4.9, 4.3, 8.3, and 8.6% of 
cells, respectively, produced IFN-     (unpublished data). Be-
cause of the loss of tetramer binding at 37  °  C as compared with 
0  °  C with these human WT1-specifi  c TCR chains, the K  D   
could not be calculated at 37  °  C (  Table I  ). Thus, in contrast to 
(v    13-D3  c-90  ) and c-116 in the constant domain of the      
chain (v    6  c-116  ;   Fig. 1  ). CD8  +   T cells were retrovirally trans-
duced with vectors encoding for WT or combinations of 
WT and     TCR chains. T cells transduced with each of these 
diff  erent pairs of chains exhibited equivalent amount of v    6 
chain at the cell surface (unpublished data). Transduced 
T cells were stimulated with K562-A2 cells pulsed with ti-
trated amounts of MDM2  81-88   peptide, the number of IFN-
      –  secreting cells was determined by an IFN-     ELISPOT 
assay (unpublished data), and     log  EC50   was calculated for 
CD8  +  -transduced T cells. The results (  Fig. 6 A  ) revealed that 
removal of the   N  -glycoslyation site in the      chain at position 
c-90 signifi  cantly increased functional avidity (v    13-D3  c-90  /
v    6  WT  ,     log  EC50   = 0.9 and P = 0.02).   Removal of other   N  -
glycosylation sites also appeared to increase functional avid-
ity, but these changes did not reach statistical signifi  cance 
(v    13-D3  v-24  /v    6  WT  ,     log  EC50   = 0.3 and P = 0.55; v    13-
D3  WT  /v    6  c-116  ,     log  EC50   = 0.8 and P = 0.07; and v    13-D3  c-90  /
v    6  c-116  ,     log  EC50   = 0.3 and P = 0.15). As described with the 
tetramer binding of v    3/v    3 TCR-transduced T cells, the 
K  D   of v    13-D3  WT  /v    6  WT   and v    13-D3  c-90  /v    6  WT   was as-
sessed by Scatchard analysis and by determining tetramer as-
sociation and dissociation (  Table I  ). As observed for v    3/v    3 
TCR  –  transduced T cells, the K  D   was only slightly decreased 
for     TCR-transduced T cells when analyzed by Scatchard 
(v    13-D3  WT  /v    6  WT  , 14 nM; v    13-D3  c-90  /v    6  WT  , 12 nM). 
However, the more precise K  D   calculation determined from 
the tetramer association and dissociation rates revealed an 
approximately threefold decrease in K  D   for     TCR as com-
pared with WT TCRs (v    13-D3  WT  /v    6  WT  , 30 nM; v    13-
D3  c-90  /v    6  WT  , 10 nM), consistent with the higher functional 
avidity of     TCR- as compared with WT TCR  –  trans-
duced T cells. 
  To determine if human TCR chains might also benefi  t 
from the removal of   N  -glycoslyation sites, human HLA-A2  –
  restricted TCR chains (v    21  WT  /v    21  WT  ) specifi  c for the tu-
mor antigen epitope WT1  126-134   were modifi  ed at the unique 
position v-83 in the variable domain (v    21  v-83  ); positions c-
36, c-90, and c-109 in the constant domain of the      chain 
(v    21  c-36  , v    21  c-90  , and v    21  c-109  ); or position c-85.6 in the 
     chain (v    21  c-85.6  ). Human CD8  +   T cells were retrovirally 
transduced with vectors encoding WT or combinations of 
WT and     TCR chains and were selected for equivalent 
levels of v    21 by fl  ow cytometry (unpublished data). To 
formally assess v    21 expression, mRNA was isolated from 
transduced CD8  +   T cells, reverse transcribed into cDNA, and 
analyzed with PCR primers detecting the unique CDR3 do-
main of the TCR      chain and normalized to the number of 
    -actin copies. Equivalent amounts of WT and     v    21 RNA 
were detected in cells previously selected based on equivalent 
v    21 surface expression. Transduced CD8  +   T cells, con-
trolled for equivalent amounts of introduced          TCR chains, 
were stimulated with T2 cells pulsed with WT1  126-134   peptide 
(10      5   M), and the number of IFN-      –  producing cells was de-
termined by an intracellular cytokine secretion assay. Cells 
transduced with v    21  c-36  /v    6  WT   exhibited the greatest activ-
    Figure 6.         Analysis of T cells transduced with TCRs of other speci-
fi  cities.   (A)    log EC50   of WT and    v  13-D3/v  6  TCR – transduced  CD8 +  
T cells. Statistical signifi  cance was assessed by a   t   test (*, P   <   0.05; error bars 
are SEM of at least two independent experiments). (B) Intracellular IFN-     
secretion of v   21 WT /v  21 WT   and  v  21 c-36 /v  21 WT   TCR – transduced  CD8 +  
T cells was determined after a 5-h coincubation with T2 cells pulsed with 
10     5   M  WT1 126-134   peptide. Data are representative of three independent 
experiments. (C) Mock (white), v   3 c-90 /v  3 WT   (light gray), v   13-D3 c-90 /v  6 WT  
(dark gray), and v   21 c-36 /v  21 WT   (black)   –  transduced T cells (from the left to 
right per cell line) were coincubated with HLA-A2  –  positive PBMCs, the 
fi  broblast cell line MRC5, and CD34  +   cells pulsed with no peptide or 10     6   M 
MDM2  81-88   as a positive control for the potential to be recognized by a spe-
cifi  c T cell in this assay, and IFN-     secretion was measured by an ELISPOT 
assay. T2 cells were pulsed with no peptide or the relevant peptide (10     6   M) 
for each TCR-transduced T cell (MDM2  81-88   for the mock-transduced T cells). 
Data are representative of two independent experiments. *, not done.    JEM VOL. 206, February 16, 2009 
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T cells has been reported to induce therapeutic responses in 
nonobese diabetic (NOD)/severe combined immunodefi  -
ciency (SCID) mice without detectable xenoreactivity (  5  ) 
with the mouse MHC molecules. This has allowed us to test 
if the physiological levels of WT1  126-134   in any tissue might be 
recognized by WT1  126-134    –  specifi  c TCR-transduced human 
T cells in vivo by transferring the human T cells into NOD/
SCID mice bred to express a transgenic HLA-A2 allele (HLA-
A2   ×   NOD/SCID), as well as if aberrant reactivity with nor-
mal host proteins presented in the context of HLA-A2 is 
acquired by the modifi  ed TCR. 2   ×   10  6   v    21  WT  /v    21  WT   
and v    21  c-36  /v    21  WT   TCR  –  transduced human T cells were 
selected for equivalent TCR expression as described in earlier 
experiments, labeled with CFSE, and intravenously injected 
into HLA-A2   ×   NOD/SCID or NOD/SCID mice. HLA-
A2   ×   NOD/SCID mice were simultaneously immunized to 
facilitate engraftment with 10   μ  g WT1  126-134   peptide or 10   μ  g 
of the control A/PR/8/34 infl   uenza matrix protein M1 
FluM1  58-66   (  33  ). NOD/SCID mice were immunized only 
with 10   μ  g WT1  126-134   peptide. 6 h later, mice received a sin-
gle subcutaneous injection of 6   ×   10  5   IU of rhIL-2 resus-
pended in incomplete Freund  ’  s adjuvant (  34  ) to enhance 
in vivo activation, survival, and expansion of the transferred 
cells. Mice were monitored for overall survival, weight loss, 
and persistence of the transferred transduced T cells. CD8  +   
T cells transduced with WT and mutated TCR chains were 
detected by fl  ow cytometry in the peripheral blood of HLA-
A2   ×   NOD/SCID mice immunized with theWT1  126-134   
peptide 2 wk after cell transfer (  n   = 8; mean v    21  WT  /v    21  WT  , 
1%; mean v    21  c-36  /v    21  WT  , 1.3%), whereas   <  0.5% of T cells 
(below the detection threshold) were detectable at 2 wk in 
HLA-A2   ×   NOD/SCID mice immunized with FluM1  58-66   or 
NOD/SCID control mice immunized with the WT1 peptide 
but that lack the HLA-A2 allele on host cells required to present 
the peptide (  n   = 16), suggesting that antigen-specifi  c pro-
liferation of TCR-transduced T cells was induced by the pep-
tide binding to recipient HLA-A2 in vivo (Fig. S4 A, available 
at http://www.jem.org/cgi/content/full/jem.20082487/DC1). 
In vivo proliferation of T cells after transfer and immuni-
zation was confi  rmed by analyzing the dilution of CFSE 
in the transferred CD8  +   T cells, which was not diluted on day 
0 but became diluted after 2 wk in immunized mice express-
ing HLA-A2 (Fig. S4 B). HLA-A2   ×   NOD/SCID mice in 
which proliferation of T cells with WT and mutated TCR 
chains was observed did not show any clinical sign of autoim-
munity after 2 wk and remained healthy through a 4-wk 
observation period, suggesting no signifi  cant toxicity medi-
ated by the transferred T cells. After 4 wk, a time when trans-
ferred T cells could no longer be detected in the peripheral 
blood (unpublished data), the HLA-A2   ×   NOD/SCID mice 
were killed, organs (liver, spleen, and lung) were analyzed 
for histological signs of autoimmune injury, and bone mar-
row and spleen cells were analyzed by fl  ow cytometry for 
the presence of CD8  +   T cells. No infi  ltrating human T cells 
were observed in the liver, lung, and bone marrow, and a 
normal histological structure of the liver, lung, and spleen 
mouse TCR chains, removal of the   N  -glycosylation motif in 
the      chain at the interspecies conserved position c-90 did 
not improve functional avidity; however, depletion of the c-
36 (  Fig. 6 B  ) in the human      chain showed an almost 3.4-fold 
increase in cytokine-secreting cells, indicating that removal of 
  N  -glycosylation sites in a human TCR chain can also im-
prove the avidity of TCR-transduced T cells. 
  Gain of functional avidity mediated by   N  -deglycosylated 
TCR chains does not result in self-reactivity 
  An undesirable eff  ect of an increased avidity of a tumor anti-
gen  –  specifi  c T cell might be the recognition of normal tissue 
either by aberrant recognition of self-antigens (  26  ) or recog-
nition of the specifi  cally targeted tumor antigen, such as WT1 
(  27  ), p53 (  28  ), or MDM2 (  3  ), because of the physiological 
expression of the protein at lower levels in normal tissues. To 
test whether the increased avidity provided by deglycosyl-
ation of the human WT1  126-134    –  , mouse p53  264-272    –  , or mouse 
MDM2  81-88    –  specifi  c HLA-A2  –  restricted TCR chains results 
in aberrant recognition of normal tissue, CD8  +   T cells were 
mock transduced or transduced with the unmodifi  ed TCR      
chain and the matched TCR      chains depleted for the   N  -
glycosylation motif at position c-36 (human) or c-90 (mouse), 
and were coincubated with a panel of normal HLA-A2  –  posi-
tive cells (PBMCs, the fi  broblast cell line MRC5, and CD34  +   
cells). As a positive control for the ability of these targets to 
be recognized, the target cells were also evaluated after puls-
ing with MDM2  81-88   at 10      6   M. All of these cell lines have 
previously been demonstrated not to be recognized by T cells 
transduced with the WT TCR chains used in this study, and 
recognition of the potential partial HLA mismatch by endog-
enous TCRs has previously been shown not to read out in 
this assay (  3, 4, 9, 21  ). As an additional positive control for 
the activity of TCR-transduced T cells, T2 cell targets were 
either not pulsed or pulsed with the relevant peptide (10      6   
M). IFN-     secretion was measured by ELISPOT, and the 
reactivity of mock- and     TCR-transduced T cells was com-
pared.     TCR-transduced T cells, similar to mock-transduced 
T cells, failed to recognize normal tissue targets (  Fig. 6 C  ), 
whereas these normal target cells pulsed with the MDM2 
peptide induced IFN-     secretion by T cells transduced with 
this     TCR, suggesting that the normal target cells could be 
recognized but that the gain of functional avidity mediated 
by the   N  -deglycosylated TCR chains does not result in ac-
quisition of self-reactivity against this set of normal cells. 
  With the modifi  ed WT1-specifi  c TCR, which was ini-
tially isolated from a normal human peripheral repertoire, it 
was also possible to analyze for potentially harmful in vivo re-
activity with normal tissues in mice transgenic for human 
HLA-A2. The tissue distribution of expression of WT1 in 
normal tissues in mice is nearly identical to humans (  29, 30  ), 
the sequence of the human epitope recognized by the human 
WT1  126-134    –  specifi   c TCR is 100% identical in the mouse 
WT1 gene, the WT1  126-134   epitope has been shown to be ef-
fi  ciently processed and presented by mouse cells (  31, 32  ), and 
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might be more readily achieved in the context of reduced   N  -
glycosylated appendages on the TCR chains. 
  Enhanced tetramer staining of     TCR- compared with 
WT TCR  –  transduced T cells was observed in our studies at 
37  °  C but not 4  °  C, indicating that temperature-dependent 
mechanisms are involved in the improved TCR  –  pMHC in-
teraction. More detailed analysis revealed that tetramer dis-
sociation was signifi  cantly prolonged (up to approximately 
ninefold), whereas tetramer association was stable (  36, 37  ). 
Thus, the observed improved binding of pMHC complexes 
and functional avidity of transduced cells was a consequence 
of the TCR complexes remaining associated for longer peri-
ods after binding had occurred rather than a result of binding 
more quickly. Structural analysis of   N  -linked oligosaccharide 
in the constant domain (  Fig. 7  ) excluded that sugars linked 
to the constant TCR domains directly interact with a pMHC 
ligand.   The slow off   rate could therefore refl  ect either greater 
clustering/multimerization or the assumption of a confor-
mation after pMHC interaction that binds more avidly, and 
either event would be expected to be temperature depen-
dent. Moreover, directly enhanced signaling through com-
plexes formed by     TCR as compared with WT TCR chains 
is also suggested by the rather small improvement in tetramer 
binding at 37  °  C that was associated with the more impres-
sive improvement in function. 
  The CD8 complex was not required for mediating the 
phenotype observed in     TCR- as compared with WT 
TCR  –  transduced T cells, as indicated by the improved func-
tional avidity detected in CD4  +  CD8        T cells transduced with 
a TCR previously demonstrated to be capable of eliciting a 
CD8-independent signal (  4  ). The lack of a requirement for 
CD8 is consistent with the structural analysis of the interaction 
site between CD8 and the TCR  –  pMHC, which is devoid of 
carbohydrates (  38  ). Moreover, in cells expressing the CD8 
was observed. Transduced T cells were detected in the spleen 
of mice that received T cells with mutated TCR chains 
(v    21  c-36  /v    21  WT  , 6.6%) but were below the detection 
threshold in recipients of T cells with WT TCR chains 
(v    21  WT  /v    21  WT  ,   <  0.5%; Fig. S4 C). Thus, the increased 
avidity of T cells transduced with the     TCR for targets pre-
senting WT1 resulted in a greater initial expansion in response 
to in vivo immunization and improved long-term persistence 
without evidence of toxicity to normal tissues. 
    DISCUSSION   
  We observed enhanced functional avidity as refl  ected by cy-
tokine secretion and lytic capacity after recognition of pep-
tide-loaded targets, and improved recognition of tumor cells 
by T cells harboring     TCR. This was observed with both 
TCRs that exhibited a high affi   nity in their WT form (  3, 4  ) 
and a TCR that initially exhibited a more intermediate affi   n-
ity (  9  ). Reducing   N  -glycosylation of TCRs might be directly 
enhancing the interaction of TCRs with pMHCs and thereby 
increasing T cell activation. Two models have been proposed 
to explain how TCR  –  pMHC interactions result in T cell 
activation (  24, 35  ). The kinetic proofreading model proposes 
that the signaling machinery of T cells becomes activated 
once an activation threshold based on the time of occupancy 
of the TCR  –  CD3 cluster by the pMHC is reached, and the 
alternative model proposes that the agonist pMHC induces a 
specifi  c conformational change in the TCR  –  CD3 that aff  ects 
the quality of signals emanating from the ligated TCR  –  CD3 
complex. In the former model, events such as TCR cluster-
ing/multimerization would be anticipated to contribute to 
the time of occupancy by increasing the number of concur-
rent interactions, and     TCR appendages might enhance 
T cell activation by facilitating TCR multimerization (  24, 35  ). 
In the latter model, the requisite conformational changes 
    Figure 7.         Molecular surface representation of the 2C TCR.   Molecular surface representation of the 2C TCR (available from the Protein Data Bank un-
der accession no.   1TCR  ; reference   52  ), colored by chain (    , yellow;     , blue) and CDR region (    -CDRs, orange;     -CDRs, purple), showing the location of as-
paragine residues at   N  -linked oligosaccharide sites (green). Two views are shown, rotated by 180  °   around the vertical axis. Ordered   N -linked  oligosaccharides 
are shown in the space-fi  lling atom representation, colored by atom type (carbon, gray; nitrogen, blue; oxygen, red) when present in the 2C crystal structure.   JEM VOL. 206, February 16, 2009 
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p53 overexpressing cell lines MDAMB231 (breast cancer) and SW480 
(colorectal cancer), were obtained from the American Type Culture Collec-
tion, and the cell line MZ1851RC (renal cell cancer) was obtained from B. 
Seliger (University of Halle, Halle, Germany). The HLA-A2  –  positive 
normal fi  broblast cell line MRC5 was obtained from the American Type 
Culture Collection, and PBMCs and CD34  +   cells were isolated from 
leukaphereses of HLA-A2  –  positive healthy donors. The retroviral packag-
ing cell line Phoenix-Ampho was obtained from the American Type Cul-
ture Collection. The HLA-A2  –  positive p53-negative tumor cell line Saos2 
(osteosarcoma) was a gift of A. Levine (Princeton University, Princeton, 
NJ), and the K562-A2 (myeloblastic) cell line was provided by T. W  ö  lfel 
(University of Mainz, Mainz, Germany). 
  WT and modifi  ed TCR chains, and TCR-transduced T cell lines.   
  p53  264-272    –  specifi  c (v    3/v    3, mouse) (  4  ), MDM2  81-88    –  specifi  c (v    13-D3/
v    6, mouse) (  3  ), and WT1  126-134    –  specifi  c (v    21/v    21, human) (  9  ) TCR 
chains are described in   Fig. 1 A  .   N  -glycosylation-sites (  N-X-S/T  ) of      and      
TCR chains are indicated in   Fig. 1 (B and C)   and are depicted according to 
the international IMGT system (available at http://imgt.cines.fr/) (  20  ). The 
prefi  x   “  v  ”   was added if the   N  -glycosylation site was located in the variable 
domain, and the prefi  x   “  c  ”   as added if it was located in the constant domain. 
To prevent   N  -glycosylation of TCR chains, the N in the   N  -glcyosylation 
site was changed to Q by site-directed mutagenesis (primers are shown in 
Table S1, available at http://www.jem.org/cgi/content/full/jem.20082487/
DC1). Successful mutagenesis was confi  rmed by sequencing. This modifi  ca-
tion has been shown to prevent   N  -glycosylation of TCR chains (  43  ). The 
WT1  126-134   TCRs have been further modifi  ed by introducing point muta-
tions in the constant domains of both chains, as previously described to insert 
cysteines that can form a disulfi  de bond and improve matched pairing and 
surface expression (  9  ). T cell transduction with modifi  ed and WT TCR 
chains was performed as previously described (  44  ). In brief, Phoenix-Ampho 
cells were transfected using a transfection reagent (Fugene; Takara) with vec-
tors containing the TCR chain (pBullet), gag-pol (pHIT60), and env 
(pCOLT-GALV) (  3  ). Human PBMCs activated with 30ng/ml     CD3 were 
transduced twice within 48 h in the presence of 40  –  100 IU/ml IL-2 and 4 
  μ  g/ml polybrene (Sigma-Aldrich), with a packaging cell supernatant contain-
ing retroviral vectors encoding for no protein (empty cassette), GFP (con-
trol), or      or      TCR chains. Downstream of the coding regions, IRES-puro 
(coding region: empty cassette or      chain) and -neo (coding region: empty 
cassette, GFP, or      chain; BD) cassettes were attached, respectively. Trans-
duced T cells were expanded by weekly stimulation with     CD3/CD28 Dy-
nabeads (1   μ  l per 10  6   cells; Invitrogen) and 40  –  100 IU/ml rhIL-2, and were 
selected with 800   μ  g/ml geneticin (Invitrogen) and 5   μ  g/ml puromycin 
(Sigma-Aldrich) for 1 wk. Polyclonal CD4  +   and CD8  +   T cells transduced 
with      and      chains were sorted based on CD4 or CD8 expression and the 
level of TCR      chain surface expression and were expanded in vitro using 
the rapid expansion protocol, as previously described (  45  ). 
  RT-PCR, fl  ow-cytometry, and T cell assays.     Expression of introduced 
     and      TCR chain was quantifi  ed by fl  ow cytometry using antibodies with 
specifi  city for the      chain, or by real-time PCR (TaqMan; Applied Biosys-
tems) by using primers specifi  c for the unique CDR3 region of the      and      
chains. Standard   51  Cr-release (  46  ), intracellular cytokine staining (  47  ), ELISA 
(  48  ), and IFN-     ELISPOT assays (  33  ) were performed as previously de-
scribed. To assess the functional avidity of TCR-transduced cells, the EC50 
(the concentration of peptide needed for half maximal cytokine secretion) 
was calculated and transformed to log  EC50     ±   SEM. To normalize gain of 
functional avidity for cells with      as compared with WT TCR chains,   “  log 
change in functional avidity  ”   (    log  EC50  ) was calculated by subtracting lo-
g  EC50   from cells transduced with     TCR chains, from log  EC50   of cells trans-
duced with WT TCR chains. To assess avidity (K  D  ) for TCR  –  pMHC 
binding, TCR-transduced cells were incubated with varying concentrations 
of tetramer for 45 min to achieve equilibrium. MFI of tetramer binding was 
determined by fl  ow cytometry and plotted against the concentration of tet-
ramer used for staining. The avidity (K  D  ) was derived from the slope by 
coreceptor, the relative improvement in functional avidity as a 
result of expressing     TCR chains did not exceed the relative 
improvement in CD4  +  CD8        T cells, suggesting that modifi  ed 
interactions of the deglycosylated TCR chain with CD8 were 
likely not playing a major role in the observed change in func-
tional avidity. Although our analysis of mutated TCRs that are 
CD8 dependent (mouse, v    13-D3/v    6; and human, v    21/
v    21) did not reveal that such TCRs become CD8 indepen-
dent after transduction into CD4  +   T cells (unpublished data) 
despite evidence of improved avidity if expressed in CD8  +   T 
cells, this more likely refl  ected the magnitude of change to 
achieve CD8 independence with these TCRs rather than a 
dependence on interaction with CD8. 
  Multiple mechanisms have been proposed to infl  uence 
the fi  ne tuning of T cell responsiveness, including modulation 
of glycosylation of the CD8 molecule (  18  ). Although regula-
tion of   N  -glycosylation has been reported to aff  ect T cell 
function (  39, 40  ), and T cells in distinct diff  erentiation states 
exhibit diff  erent levels of glycosylation (immature/mature 
and naive/memory) (  15, 16  ), there has been no direct evi-
dence that altered   N  -glycosylation of TCR chains is a physio-
logical mechanism to tune reactivity via modulating avidity. 
For example, activation of naive T cells could result in re-
duced   N  -glycosylation of TCR chains that could contribute 
to the improved functional avidity observed in antigen-expe-
rienced T cells. Diff  erentially   N  -glycosylated TCR complexes 
have also been observed in mature CD4 as compared with 
CD8 T cells (  41  ), but the role of such diff  erential   N  -glycosyl-
ation in defi  ned T cell subsets has not yet been investigated. 
  In summary, we demonstrate that reduced   N  -glycosyl-
ation of TCR chains can improve functional avidity of 
TCR-transduced T cells in the absence and presence of the 
coreceptor CD8. We suggest that removal of specifi  c   N  -gly-
cosylation sites, in particular c-90 in the mouse TCR      chain, 
allows a temperature-dependent change, such as improved 
TCR multimerization resulting in a diminished TCR  –  pMHC 
dissociation and, therefore, more effi   cient T cell activation. 
Regardless of the individual mechanisms, this strategy can 
improve the avidity and potentially the effi   cacy of TCR-
transduced T cells and may therefore prove useful for current 
eff  orts to redirect the immune system against cancer cells. 
  MATERIALS AND METHODS 
  Peptides, antibodies, multimeric complexes, and cytokines.     Pep-
tides p53  264-272  , MDM2  81-88  , and WT1  126-134  , and the A/PR/8/34 infl  u-
enza matrix protein M1 FluM1  58-66   were synthesized by SynPep. 
Anti  –  human  –  CD8  –  FITC/PerCP/PCY5 and anti  –  human  –  v    21  –  FITC 
(Beckman Coulter), and anti-mu    /muv    3/muv    6TCR  –  PE/Pcy5 (BD) were 
commercially obtained. PE-labeled p53  264-272  , MDM2  81-88  , and WT1  126-134   
tetramer HLA-A2 complexes were synthesized as previously described 
(  42  ). Capture/detector antibody pairs for use in IL-2 and IFN-     ELISA 
analysis were purchased from R  &  D Systems. IFN-     ELISPOT was per-
formed with 1D1K and 7B61 capture and detection antibodies (Mabtech). 
IL-2 was obtained from Chiron, and     CD3 (OKT3; Muromonab) was 
obtained from Ortho-Biotec. 
  Cell lines.     The TCR-defi  cient cell line 58                       was provided by B. Malis-
sen (Centre d  ’   Immunologie Marseille-Luminy, Marseille, France). The 
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body was added, and the MFI of tetramer binding after 2, 5, 10, 15, 20, 40, 
and 60 min was again determined. Only in the presence of the blocking 
antibody W6/32 was a decrease in the MFI of tetramer binding observed. 
Furthermore, the number of TCR complexes, as assessed by a v    -specifi  c 
monoclonal antibody before and after incubation at 37  °  C, were identical in 
WT- and     TCR-transduced T cells, suggesting no diff  erence in endocyto-
sis of TCR complexes during the time of the dissociation experiment. The 
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culated (k  on   = (k  ob        k  off    )/ligand concentration; K  D   = k  off    /k  on  ). 
  Adoptive T cell transfer.     NOD/SCID mice were bred to express a trans-
genic HLA-A2 allele (HLA-A2   ×   NOD/SCID). Irradiated (150 rad) NOD/
SCID or HLA-A2   ×   NOD/SCID mice were intravenously injected with 2   ×   
10  6   human v    21  WT  /v    21  WT   and v    21  c-36  /v    21  WT   TCR  –  transduced T cells 
selected for equivalent TCR expression, as described in earlier experiments, 
labeled with CFSE. The HLA-A2   ×   NOD/SCID and NOD/SCID mice were 
then immediately immunized subcutaneously once with 10   μ  g WT1  126-134   
peptide or the A/PR/8/34 infl  uenza matrix protein FluM1  58-66   (  33  ), as indi-
cated in the fi  gures, and this was followed 6 h later by a single subcutaneous 
injection of 6   ×   10  5   IU rhIL-2 resuspended in incomplete Freund  ’  s adjuvant. 
Peripheral blood was obtained by tail bleeding after 2 and 4 wk. Mice were 
propagated and maintained at the Johannes Gutenberg University. Animal 
experiments were approved by the local authorities (Landesuntersuchungsamt 
Rheinland Pfalz, Dienststelle Tierschutz, Mainz, Germany). All experimental 
procedures were performed according to the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. 
  Online supplemental material.     Fig. S1 shows TCR      chain staining of 
    TCR-transduced 58                       hybridoma cells, Fig. S2 shows tetramer staining 
of     TCR-transduced 58                       hybridoma cells, and Fig. S3 shows TCR in-
ternalization after antigen encounter. Fig. S4 shows antigen-specifi  c in vivo 
proliferation of TCR-transduced T cells. Table S1 shows primers used for 
site-directed mutagenesis. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20082487/DC1. 
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